Altre lingue Biogen Inc. Sao Paulo

Azioni

BIIB34

BRBIIBBDR001

Mercato chiuso - Sao Paulo Altri mercati azionari 16:25:03 25/04/2024			Variaz. 5gg	Var. 1 gen.
171,4 ^BRL	-2,16%		-.--%	-16,49%

31/05	La Commissione Europea concede l'autorizzazione all'immissione in commercio del farmaco per la SLA di Biogen	RE
30/05	Biogen ottiene l'approvazione della Commissione europea per Qalsody	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

European Commission grants marketing approval to Biogen's ALS drug	31/05
Biogen Gets European Commission Approval for Qalsody	30/05
US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns	22/05
Sector Update: Health Care Stocks Slightly Higher Late Afternoon	22/05
Sector Update: Health Care Stocks Advance Wednesday Afternoon	22/05
Sector Update: Health Care	22/05
Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion	22/05
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	22/05
BIOGEN INC. : Wedbush maintient son opinion neutre	22/05
Biogen to Acquire Human Immunology Biosciences for up to $1.8 Billion	22/05
Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal	22/05
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	16/05
Sector Update: Health Care Stocks Ease Thursday Afternoon	16/05
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	16/05
Sector Update: Health Care	16/05
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	16/05
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	16/05
Sector Update: Health Care Stocks Steady Premarket Thursday	16/05
Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results	16/05
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	16/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Biogen Inc. Sao Paulo

Azioni

BIIB34

BRBIIBBDR001

Altre lingue

Filtri